FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1372 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR “That is what I dream”: India’s journey to rolling out the... November 17, 2021 Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... May 21, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab June 5, 2025 ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... June 12, 2026 Load more HOT NEWS Food for Thought: A Fresh Perspective on Nutrition Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer 2022 ASCO Annual Meeting Research Round Up: New Research in Head... Using a Mind-Body Connection to Help You Cope During Cancer: An...
